{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:05:13Z","timestamp":1785150313045,"version":"3.55.0"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T00:00:00Z","timestamp":1234828800000},"content-version":"vor","delay-in-days":1539,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>The present study examined the ability of the selective imidazoline I<jats:sub>2<\/jats:sub>\u2010site ligands 2\u2010(\u20102\u2010benzofuranyl)\u20102\u2010imidazoline (2\u2010BFI) and 2\u2010[4,5\u2010dihydroimidaz\u20102\u2010yl]\u2010quinoline (BU224) and selected monoamine oxidase (MAO) inhibitors to evoke locomotor activity in rats bearing a lesion of the nigrostriatal pathway.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Male Sprague\u2013Dawley rats were injected with 12.5 <jats:italic>\u03bc<\/jats:italic>g 6\u2010hydroxydopamine (6\u2010OHDA) into the right median forebrain bundle to induce a unilateral lesion of the nigrostriatal tract. After 6 weeks, test drugs were administered either alone or in combination with <jats:sc>L<\/jats:sc>\u2010DOPA (<jats:sc>L<\/jats:sc>\u20103,4\u2010dihydroxyphenylamine) and the circling behaviour of animals was monitored as an index of anti\u2010Parkinsonian activity.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Intraperitoneal (i.p.) administration of the irreversible MAO\u2010B inhibitor deprenyl (20 mg kg<jats:sup>\u22121<\/jats:sup>) or the imidazoline I<jats:sub>2<\/jats:sub>\u2010site ligands BU224 (14 mg kg<jats:sup>\u22121<\/jats:sup>) and 2\u2010BFI (7 and 14 mg kg<jats:sup>\u22121<\/jats:sup>) produced significant increases in ipsiversive rotations compared to vehicle controls totaling, at the highest respective doses tested, 521\u00b1120, 131\u00b137 and 92.5\u00b116.3 net contraversive rotations in 30 (deprenyl) or 60 (BU224 and 2\u2010BFI) min. In contrast, the reversible MAO\u2010A inhibitor moclobemide (2.5\u201310 mg kg<jats:sup>\u22121<\/jats:sup>) and the reversible MAO\u2010B inhibitor lazabemide (2.5\u201310 mg kg<jats:sup>\u22121<\/jats:sup>) failed to instigate significant rotational behaviour compared to vehicle.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Coadministration of lazabemide (10 mg kg<jats:sup>\u22121<\/jats:sup>), moclobemide (10 mg kg<jats:sup>\u22121<\/jats:sup>) or 2\u2010BFI (14 mg kg<jats:sup>\u22121<\/jats:sup>) with <jats:sc>L<\/jats:sc>\u2010DOPA (20 mg kg<jats:sup>\u22121<\/jats:sup>) significantly increased either the duration or total number of contraversive rotations emitted over the testing period in comparison to <jats:sc>L<\/jats:sc>\u2010DOPA alone.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>These data suggest that I<jats:sub>2<\/jats:sub>\u2010specific ligands have dual effects in the 6\u2010OHDA\u2010lesioned rat model of Parkinson's disease; a first effect associated with an increase in activity in the intact hemisphere, probably <jats:italic>via<\/jats:italic> an increase in striatal dopamine content, and a secondary action which, through the previously documented inhibition of MAO\u2010A and\/or MAO\u2010B, increases the availability of dopamine produced by <jats:sc>L<\/jats:sc>\u2010DOPA.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2004) <jats:bold>143<\/jats:bold>, 952\u2013959. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0706019\">10.1038\/sj.bjp.0706019<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0706019","type":"journal-article","created":{"date-parts":[[2004,11,16]],"date-time":"2004-11-16T01:12:53Z","timestamp":1100567573000},"page":"952-959","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Locomotor effects of imidazoline I<sub>2<\/sub>\u2010site\u2010specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6\u2010hydroxydopamine lesion of the nigrostriatal pathway"],"prefix":"10.1111","volume":"143","author":[{"given":"Nicholas","family":"MacInnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13280.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.064782"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(81)90346-1"},{"key":"e_1_2_8_5_1","first-page":"391","article-title":"Pharmacological profile of moclobemide, a short\u2010acting and reversible inhibitor of monoamine oxidase type A","volume":"248","author":"BURKWARD W.P.","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb04587.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00413-3"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32400.x"},{"key":"e_1_2_8_9_1","first-page":"798","article-title":"Effects of alpha\u20102 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6\u2010hydroxydopamine lesions of the nigrostriatal pathway","volume":"288","author":"CHOPIN P.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"e_1_2_8_10_1","first-page":"10","article-title":"Ro 19\u20106327, a novel highly selective and reversible MAO\u2010B inhbitor","volume":"60","author":"DA PRADA M.","year":"1987","journal-title":"Pharmacol. Toxicol."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(98)01244-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(94)90116-3"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.202"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(96)00035-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01291878"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(80)90353-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(81)90342-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09344.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00562-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200009000-00003"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119601000403"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb00650.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09350.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702389"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.1_suppl_1.S9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00389-6"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01259-6"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704579"},{"key":"e_1_2_8_29_1","first-page":"270","article-title":"Keeping an eye on the I site: Imidazoline\u2010preferring receptors","volume":"13","author":"MICHEL M.C.","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(02)00842-0"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(96)00132-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32397.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.12.023"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701214"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540160036006"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400116"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.561"},{"key":"e_1_2_8_39_1","volume-title":"The Rat Brain in Stereotaxic Co\u2010ordinates","author":"PAXINOS G.","year":"1998"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020070083"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(80)90048-2"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.52.4.549"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/mol.58.5.1085","article-title":"Analysis of the pharmacological and molecular heterogeneity of I2\u2010imidazoline\u2010binding proteins using monoamine oxidase\u2010deficient mouse models","volume":"58","author":"REMAURY A.","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00196-3"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02076-9"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)01599-3"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00001"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-201X.1971.tb11000.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706019","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0706019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:14:48Z","timestamp":1697242488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0706019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1038\/sj.bjp.0706019"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0706019","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"2009-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}